State of Alaska Department of Revenue’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

State of Alaska Department of Revenue’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,130	Closed	-$202K	–	1648
2023 Q1	$202K	Sell	7,130 -121	-2%	-$3.59K	﹤0.01%	1595
2022 Q4	$211K	Sell	7,251 -107	-1%	-$3.4K	﹤0.01%	1592
2022 Q3	$194K	Sell	7,358 -1,091	-13%	-$40K	﹤0.01%	1585
2022 Q2	$375K	Buy	8,449 +540	+7%	+$24.8K	﹤0.01%	1468
2022 Q1	$391K	Sell	7,909 -140	-2%	-$6.72K	﹤0.01%	1478
2021 Q4	$409K	Sell	8,049 -360	-4%	-$18.7K	﹤0.01%	1528
2021 Q3	$469K	Buy	8,409 +335	+4%	+$16.5K	﹤0.01%	1486
2021 Q2	$345K	Buy	8,074 +220	+3%	+$9.08K	﹤0.01%	1554
2021 Q1	$327K	Sell	7,854 -1,170	-13%	-$54.3K	﹤0.01%	1546
2020 Q4	$420K	Sell	9,024 -2,300	-20%	-$108K	﹤0.01%	1432
2020 Q3	$481K	Buy	11,324 +2,020	+22%	+$88.4K	0.01%	1257
2020 Q2	$446K	Sell	9,304 -80	-0.9%	-$3.99K	0.01%	1286
2020 Q1	$431K	Buy	9,384 +1,745	+23%	+$87.6K	0.01%	1175
2019 Q4	$458K	Sell	7,639 -132	-2%	-$7.87K	0.01%	1345
2019 Q3	$439K	Buy	7,771 +4,264	+122%	+$240K	0.01%	1328
2019 Q2	$195K	Buy	3,507 +30	+0.9%	+$1.56K	﹤0.01%	1464
2019 Q1	$175K	Sell	3,477 -240	-6%	-$10.7K	﹤0.01%	1494
2018 Q4	$149K	Buy	3,717 +110	+3%	+$5.67K	﹤0.01%	1499
2018 Q3	$250K	Buy	3,607 +905	+33%	+$68.6K	﹤0.01%	1433
2018 Q2	$204K	Hold	2,702	–	–	﹤0.01%	1479
2018 Q1	$142K	Buy	2,702 +1,010	+60%	+$58.7K	﹤0.01%	1510
2017 Q4	$90K	Hold	1,692	–	–	﹤0.01%	1535
2017 Q3	$100K	Buy	1,692 +100	+6%	+$6.05K	0.01%	1181
2017 Q2	$125K	Buy	1,592 +702	+79%	+$57.4K	0.01%	1048
2017 Q1	$73K	Buy	890 +30	+3%	+$2.23K	0.01%	1036
2016 Q4	$68K	Buy	+860	New	+$62.5K	0.01%	763

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State of Alaska Department of Revenue's EGRX Position: Q2 2023 in Review

State of Alaska Department of Revenue sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 7,130 shares — an estimated $202K sold.

State of Alaska Department of Revenue first reported a position in EGRX in Q4 2016 and held it in 26 quarters. The position peaked at $481K in Q3 2020. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

State of Alaska Department of Revenue reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
State of Alaska Department of Revenue sold 7,130 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $202K.
State of Alaska Department of Revenue first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 26 quarters.
State of Alaska Department of Revenue's Eagle Pharmaceuticals, Inc. position peaked at $481K in Q3 2020.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2023, filed 25 Jul 2023.